{"id":"W2992921938","doi":"10.1016/s1470-2045(19)30671-0","title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Pembrolizumab; Tolerability; Interim analysis; Refractory (planetary science); Internal medicine; Oncology; Cohort; Response Evaluation Criteria in Solid Tumors; Adverse effect; Clinical trial; Phases of clinical research; Cancer; Surgery; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008488912,0.0003755388,0.002165463,0.0002952968,0.0001218266,0.00003232505,0.0006754303,0.0001926578,0.0009381586],"category_scores_gemma":[0.0008800973,0.0001914248,0.00008656982,0.001550856,0.0002101928,0.0005337049,0.0003982117,0.0004869296,0.00002764383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005348611,"about_ca_system_score_gemma":0.0005216622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001279655,"about_ca_topic_score_gemma":0.001230644,"domain_scores_codex":[0.9965416,0.0008691705,0.0008501738,0.0006416919,0.0004062817,0.0006910567],"domain_scores_gemma":[0.9959361,0.002074492,0.0008716977,0.0006613256,0.0002430988,0.000213294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8556673,0.01493042,0.001471467,0.00009460417,0.001218284,0.0003425761,0.0009059074,0.00004362336,0.002235225,0.00001722159,0.000156279,0.1229171],"study_design_scores_gemma":[0.7120536,0.2180054,0.02014119,0.0002083672,0.004270619,0.00009021759,0.001558338,0.001575644,0.0009022658,0.00002307108,0.04058179,0.0005895277],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922919,0.0003644479,0.00001671905,0.001137271,0.0004503659,0.00239152,0.000149314,0.00004297522,0.003155469],"genre_scores_gemma":[0.9946181,0.0008820528,0.001447558,0.00197324,0.0002929586,0.0001478673,0.0001198911,0.00004743889,0.0004708617],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.203075,"threshold_uncertainty_score":0.9999751,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0939061329066039,"score_gpt":0.4336228266562593,"score_spread":0.3397166937496554,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}